product image
Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate

Jan 14, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration  Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clini...

Read More
product image
Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Jan 7, 2021

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The...

Read More
product image
Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

Dec 31, 2020

Improving cancer immunotherapy by recovering a warning system Cancer cells, most of the time, develop tactics to elude the immune system. A research team that is led by sci...

Read More
product image
NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

Dec 24, 2020

NIH awards USD 107 Million for radical COVID-19 testing tech  The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing fo...

Read More
product image
AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

Dec 10, 2020

AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential fo...

Read More
product image
KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

Dec 8, 2020

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agre...

Read More
product image
Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Dec 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of ...

Read More
product image
Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Against COVID; Gilead & Novo Nordisk’s Cocktail Therapy for NASH

Nov 17, 2020

Albireo Pharma Hopeful to Commercialize its PFIC Treatment by the End of the Year Albireo Pharma, spun out of AstraZeneca, has long been working on developing potential and...

Read More
product image
Pfizer’s COVID-19 Vaccine; Calliditas’ NefIgArd trial; ViiV’s HIV Prevention Treatment; Biogen’s Aducanumab Rejection

Nov 10, 2020

Pfizer’s COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, t...

Read More
product image
Cyclerion’s olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche’s gene therapy pact; RayzeBio debuts with $ 45M to target tumors

Oct 15, 2020

Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a...

Read More
product image
J&J ‘s COVID-19 vaccine; Roche, AC Immune’s anti-Tau Alzheimer’s drug; Silverback nets $85 M; Anokion’s deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development

Sep 24, 2020

J&J commences COVID-19 vaccine phase 3 Johnson & Johnson has begun a 60,000-subject phase 3 evaluation of its COVID-19 vaccine. The trial will enroll participants i...

Read More
product image
Lilly’s COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian’s CD40L cell therapy

Sep 17, 2020

Lilly links COVID-19 antibody to a reduce hospitalization rate Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients lately diagn...

Read More
product image
Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates

Sep 10, 2020

Pfizer, BioNTech report shows the immune response in animals to COVID-19  Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, eac...

Read More
product image
Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial

Sep 1, 2020

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Ne...

Read More
product image
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

Aug 20, 2020

FDA rejects BioMarin’s gene therapy and Gilead’s filgotinib over concerns The FDA refused to approve BioMarin’s hemophilia A gene therapy valoctocogene ro...

Read More